2 superb FTSE 100 stocks I’d buy for a SIPP and hold for a decade

This Fool highlights a pair of excellent blue-chip stocks that he’d buy today and tuck away in a SIPP portfolio for the long run.

| More on:
A senior group of friends enjoying rowing on the River Derwent

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Warren Buffett famously said: “If you aren’t thinking about owning a stock for 10 years, don’t even think about owning it for 10 minutes.” A self-invested personal pension (SIPP) is perfect for this mindset.

That’s because it allows me to tax-efficiently save, invest and build up a pot of money for retirement. And that might be a decade or more away.

Here are two quality FTSE 100 stocks I’d buy for a SIPP today.

Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice. Readers are responsible for carrying out their own due diligence and for obtaining professional advice before making any investment decisions.

The biggest fish

To start, I’d go with the UK’s largest company by market capitalisation: AstraZeneca (LSE: AZN). The pharma giant is just ahead of fellow Footsie heavyweight Shell in the rankings.

The stock has more than doubled in five years and nearly trebled over a decade. A combination of smart leadership, shrewd acquisitions and surging top and bottom-line growth have all driven this performance.

In 2014, the drugmaker set a target of reaching more than $45bn in revenue by 2023. Having achieved that, it’s now aiming to grow revenue to $80bn by 2030, which would be a rise of 75%.

It expects to launch 20 new medicines by then, as well as increase sales from its massive existing oncology, biopharmaceuticals, and rare diseases portfolio. And it’s targeting a mid-30% core operating profit margin, up from 28% in 2020.

While I wouldn’t bet against all that happening, the company can be hit by late-stage clinical trial failures. That’s just the nature of the beast here, as are potential litigation and regulation issues.

Nevertheless, AstraZeneca’s driving ambition is to transform oncology by replacing traditional treatments like chemotherapy and radiotherapy with more targeted treatments.

This is a vision I’m invested in myself, having added Astra shares to my portfolio a few months ago.

To my mind, an ageing global population and rising cases of cancer should naturally lead to the company becoming more valuable over time.

The journey won’t always be smooth, but this is a FTSE 100 stock I’d want in my SIPP for the long haul.

A world-class data firm

Next up, we have Experian (LSE: EXPN). This is one of the world’s largest credit reporting agencies. It provides data and analytical tools to lenders around the globe to help them make informed decisions.

Like AstraZeneca, this stock has been performing very strongly. It’s up 26% over the past year, easily outperforming the wider FTSE 100 in the process.

There are a few reasons I like Experian. For starters, it boasts strong returns on capital and equity. In its last financial year that ended in March, it achieved a very healthy 17% net profit margin.

Second, the company has credit information on over 1.4bn consumers and 191m businesses around the globe. This is almost impossible to replicate, giving it a powerful and durable competitive advantage.

Third, these high-quality datasets can be used for new analytics tools powered by artificial intelligence.

The one issue I’d highlight here though is valuation, with the stock trading at around 29 times forward earnings. That’s much higher than the FTSE 100 average, which could mean any disappointing results might send the price lower.

However, I don’t think the valuation is outrageous for a world-class data firm. I can see the stock outperforming the UK market over the next decade and plan to add it to my SIPP.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc and Experian Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

3 UK stocks I reckon could benefit from the upcoming general election

As the general election hurtles towards us, this Fool wonders which UK stocks could benefit, and focuses on three picks…

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

At 11%, this dividend share pays the biggest yield in the FTSE 100

When a dividend share offers a big yield, we need to be cautious of the risks. But I reckon this…

Read more »

British Isles on nautical map
Investing Articles

I reckon Hiscox shares could be one of the best bargains on the FTSE

I've been investing in FTSE companies for years, but after a major decline I've not seen a company with as…

Read more »

Grey Number 4 Stencil on Yellow Concrete Wall
Investing Articles

4 reasons I’d still buy National Grid shares in a heartbeat despite the recent wobble!

As National Grid shares plunged on the news of a right issue, I’m not flinching, and reckon it's a top…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

After gaining 45% in 12 months, is the Amazon share price now overvalued?

Our author thinks the Amazon share price might be too high. While the long-term future of the business looks bright,…

Read more »

Investing Articles

2 hot dividend stocks I’d buy and hold for 10 years

Our writer reckons these two dividend stocks could help her bag juicy dividends for years to come and explains why.

Read more »

British Pennies on a Pound Note
Investing Articles

2 dividend-paying penny shares I’d happily own

These two penny shares have caught our writer's eye for a combination of income prospects now and business growth potential…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

This FTSE 250 share looks like a bargain to me!

This FTSE 250 share has seen its price tumble due to chaotic local economic conditions in a key market. But…

Read more »